iguratimod has been researched along with isoxazoles in 2 studies
| Studies (iguratimod) | Trials (iguratimod) | Recent Studies (post-2010) (iguratimod) | Studies (isoxazoles) | Trials (isoxazoles) | Recent Studies (post-2010) (isoxazoles) |
|---|---|---|---|---|---|
| 134 | 19 | 109 | 8,633 | 900 | 3,337 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawabata, D; Mimori, T | 1 |
| Gu, Y; Jin, B; Liu, W; Luo, Q; Qian, C; Shen, Y; Sun, Y; Tao, F; Wu, X; Xu, Q | 1 |
1 review(s) available for iguratimod and isoxazoles
| Article | Year |
|---|---|
[Disease modifying anti-rheumatic drugs (DMARDs): an overview].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Benzopyrans; Cysteine; Evidence-Based Medicine; Gold Sodium Thiomalate; Humans; Isoxazoles; Leflunomide; Meta-Analysis as Topic; Methotrexate; Randomized Controlled Trials as Topic; Sulfasalazine; Sulfonamides | 2005 |
1 other study(ies) available for iguratimod and isoxazoles
| Article | Year |
|---|---|
A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Chromones; Collagen; I-kappa B Kinase; Inflammation; Interleukin-17; Isoxazoles; Leflunomide; Male; Methotrexate; Mice; Mice, Inbred DBA; Phosphorylation; Signal Transduction; Sulfonamides; Synovial Membrane; TNF Receptor-Associated Factor 5 | 2013 |